51例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析：多中心回顾性研究

Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen:a multicentre retrospective study

关键词:  2019冠状病毒病  新型冠状病毒肺炎  连花清瘟  临床研究  疗效分析  多中心回顾性研究

Key words:  COVID-19  novel coronavirus pneumonia  Lianhua Qingwen  clinical research  efficacy analysis  multicenter retrospective study

摘要:

[目的] 分析联合应用连花清瘟颗粒治疗新型冠状病毒肺炎的临床疗效。[方法] 采取回顾性临床研究方法，选择2020年1月在武汉科技大学附属普仁医院、武汉科技大学附属华润武钢总医院、武汉市第九医院3家医院就诊的符合新型冠状病毒肺炎普通型患者的临床资料，符合纳排标准的连花清瘟颗粒联合常规治疗患者51例为治疗组，倾向性配对1：1，常规治疗患者51例为对照组。比较两组主要症状（发热、乏力、咳嗽）消失率、持续时间、有效率，其他症状体征消失率、肺部计算机断层扫描（CT）好转率等。[结果] 两组基线资料比较，差异无统计学意义。治疗7 d后，治疗组主要症状（发热、乏力、咳嗽）消失率分别为83.7%、61.3%、62.2%，对照组为61.0%、34.3%、35.9%，两组间比较差异有统计学意义（P<0.05）；治疗组主要症状消失平均时间为（2.9±1.7）、（3.5±1.5）、（3.9±2.0） d，对照组为（3.9±1.3）、（4.8±1.5）、（5.2±1.8） d，两组间比较差异均具有统计学意义（P<0.05）；治疗组主要症状治疗有效44例（86.3%）；对照组为35例（68.6%），组间比较差异有统计学意义（P<0.05）；治疗组咳痰、气促、胸闷、食欲减退症状消失率分别为55.0%、61.5%、54.6%、34.8%，对照组为15.8%、14.3%、15.8%、7.7%，两组间比较差异有统计学意义（P<0.05）；治疗组治疗过程中转重型4例（7.8%），对照组11例（21.6%），组间比较差异有统计学意义（P<0.05）；治疗组肺部CT好转28例（54.9%）；对照组为23例（45.1%），组间比较差异无统计学意义（P>0.05）。[结论] 联合应用连花清瘟颗粒能明显改善新型冠状病毒肺炎普通型患者的发热、乏力、咳嗽、咳痰、气促、胸闷、食欲减退临床症状，提高主要症状有效率，降低普通转重型比例，提示连花清瘟颗粒可以有效地应用于新型冠状病毒肺炎普通型患者治疗中。

Abstract:

[Objective] To analyze the clinical efficacy of combined application of Lianhua Qingwen Granules (LH-C) in the treatment of novel coronavirus pneumonia (NCP).[Methods] A retrospective clinical research method was adopted to select clinically eligible patients with novel coronavirus pneumonia (NCP) in the three hospitals of Puren Hospital Affiliated to Wuhan University of Science and Technology,CR & WISCO General Hospital,and Wuhan Ninth Hospital in January 2020. Among patients meeting inclusion and exclusion criteria,51 cases receiving LH-C combined with the conventional therapy were included in the treatment group,and 51 cases receiving the conventional therapy were included in the control group,with propensity matching 1:1. The disappearance rate,duration,and effective rate of cardinal symptoms (fever,fatigue,cough),other symptoms and signs disappearance rate,lung computer tomography (CT) improvement rate were compared between two groups.[Results] There were no significant differences in baseline between two groups. After 7 days of treatment,the disappearance rate of cardinal symptom (fever,fatigue,cough) in the treatment group was 83.7%,61.3%,and 62.2%,and the control group was 61.0%,34.3%,and 35.9%. There was a statistically significant difference between the two groups (P<0.05). The average disappearance time of cardinal symptom in the treatment group was (2.9±1.7),(3.5±1.5) and (3.9±2.0) days,and the control group was (3.9±1.3),(4.8±1.5) and (5.2±1.8) days,the difference between two groups was statistically significant (P<0.05). The cardinal symptoms of the treatment group were effective in 44 cases (86.3%) and the control group was 35 cases (68.6%),and the differences between two groups was statistically significant (P<0.05). The disappearance rate of expectoration,shortness of breath,chest distress,appetite loss,and moist rale sign was 55.0%,61.5%,54.6%,34.8% in the treatment group,and 15.8%,14.3%,15.8%,7.7% in the control group. There was a statistically significant difference between two groups (P<0.05). In the treatment group,4 cases (7.8%) were converted to heavy,and 11 cases (21.6%) in the control group. The difference between two groups was statistically significant (P<0.05). There were 28 cases (54.9%) of lung CT improvement in the treatment group and 23 cases (45.1%) in the control group. There was no significant difference between two groups (P>0.05).[Conclusion] LH-C combined with a conventional therapy could significantly improve clinical symptoms of NCP patients including fever,fatigue,cough,expectoration,shortness of breath,chest distress and appetite loss,enhance the effective rate of cardinal symptom,and reduce the proportion of normal to heavy. These findings suggested LH-C could be effective in the common NCP patients.